Third Harmonic Bio, Inc. (THRD)

Market Cap	242.79M
Revenue (ttm)	n/a
Net Income	-53.45M
EPS	-1.25
Shares Out	45.13M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,417,958
Open	5.41
Previous Close	5.39
Day's Range	5.35 - 5.43
52-Week Range	3.18 - 16.02
Beta	2.13
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 7, 2025

About THRD

Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases. The company develops oral small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It also develops THB335, an oral small molecule KIT inhibitor for the treatment of mast cell-mediated inflammatory diseases, respiratory, and gastrointestinal conditions. It has a license agreement with Novarti...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 15, 2022
• Employees: 53
• Stock Exchange: NASDAQ
• Ticker Symbol: THRD
• Website: https://www.thirdharmonicbio.com

Financial Performance

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Jan 1, 2000

Data Sources Report a data error